Delhi High Court Records Turio's Undertaking To Drop 'TRU-BACT', 'TU-BACT' Marks In GlaxoSmithKline Suit

The Delhi High Court has recently recorded an undertaking by Turio Pharmaceuticals Private Limited to stop using marks similar to “T-BACT” in a trademark suit filed by GlaxoSmithKline Pharmaceuticals Limited.

Justice Jyoti Singh, on April 21, 2026, accepted an undertaking that Turio Pharmaceuticals, through its director Suresh Chaluvadi, shall not use the marks “TRU-BACT”, “TU-BACT” or any other mark identical or deceptively similar to GlaxoSmithKline's registered “T-BACT” mark or its packaging in future.

Turio Pharmaceuticals joined the proceedings virtually through Suresh Chaluvadi, who accepted summons upon receiving an advance copy of the suit.

The suit sought a permanent injunction restraining Turio Pharmaceuticals from manufacturing, selling or marketing pharmaceutical products, including ointments and skin creams, under the impugned marks or any deceptively similar branding.

Recording the undertaking, the court said it would bind Turio Pharmaceuticals and disposed of the suit after recording the undertaking in terms of the reliefs sought in the plaint.

The court also granted liberty to GlaxoSmithKline Pharmaceuticals to pursue certain reliefs in separate proceedings, if required.

Additionally, the court directed Turio Pharmaceuticals to pay costs of ₹30,000 to the Wagging Tales Foundation within six weeks.